Video

Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial (NCT02864992) evaluating patients with MET exon 14 (METex14) skipping mutation–positive non–small cell lung cancer (NSCLC).

A subgroup analysis of the VISION trial demonstrated that tepotinib (Tepmetko) elicited robust and durable clinical efficacy in patients aged 75 years and older, which was similar to the efficacy observed in subsets of younger patients.

It is important to be aware that the rare target, METex14, can be present in NSCLC histologies other than adenocarcinoma, according to Garassino. Additionally, prolonged responses can be established in this patient population with MEK and PARP inhibitors, Garassino continues. Tepotinib should be considered instead of chemotherapy in this patient population, Garassino concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity